Financial Times “Old science, known compound,” said Tahir Amin, lawyer and director at the I-MAK, the group that filed the opposition. “India’s patent law doesn’t give monopolies for old science or for compounds that are already in the public domain. We believe this patent on sofosbuvir does not deserve to be granted in India.”
Partner with us now to build a more just and equitable medicine system for all. Notice: JavaScript is required for this content.